Biologic agents and targeted therapies

Biologic and targeted therapies represent a major class of medical treatments designed to interfere with specific molecular mechanisms, cellular pathways, or components involved in carcinogenesis and the tumor microenvironment. Unlike conventional cytotoxic chemotherapy, which broadly affects rapidly dividing cells, targeted agents aim at defined vulnerabilities in cancer cells or modulate the host immune response. Biologic agents are frequently derived from living organisms—encompassing therapeutic proteins, vaccines, and engineered antibodies—whereas targeted therapies encompass small molecules and specialized inhibitors that home in on dysregulated enzymatic cascades or surface receptors. ^[1]

Evaluating the clinical efficacy of these novel agents requires careful analysis of trial design and survival outcomes, particularly when assessing progression-free survival (PFS) and overall survival (OS). A thorough understanding of trial data helps clinicians avoid discordant interpretations where post-progression survival artifacts or biased study designs obscure true clinical benefit. Across extensive analyses of clinical investigations involving biologic and targeted therapies, a total of 192 unique studies encompassing 206 pairwise comparisons between biologic or targeted regimens and comparator arms have been evaluated. ^[1]

When comparing these therapeutic classes to non-biologic or non-targeted comparators, the average absolute magnitude of post-progression survival—defined as the difference between overall survival and progression-free survival—was found to be 9.7 months for biologic and targeted therapy groups, compared with 9.8 months for comparator groups. Overall survival associated with biologic and targeted therapies ranged widely, from 9.8 months lower than the comparator up to a substantial gain of 25.4 months over the comparator. Similarly, progression-free survival associated with these advanced agents ranged from 8.2 months lower than the comparator to 14.9 months more than the comparator. On average, biologic and targeted therapies improved both overall survival and progression-free survival by an average of 1.2 months versus non-biologic and non-targeted comparators, with standard deviations of 3.8 and 2.5 months, respectively. ^[1]

A major pitfall in managing patients on biologic agents and targeted therapies is failing to recognize drug-induced secondary reactions or atypical manifestations. For instance, the majority of patients treated with anti-TNF-alpha who developed drug-induced sarcoidosis-like reactions (DISR) exhibited pulmonary involvement, whereas patients treated with other drug categories such as BRAF inhibitors showed cutaneous involvement as the most common symptom. In pulmonary sarcoidosis, alveolar macrophages spontaneously produce excessive amounts of TNF-alpha, along with interleukins IL-1, IL-2, IL-6, and IL-10, implicating these cells in the formation of non-caseating granulomas ^[2]

The clinical application of biologic agents and targeted therapies is frequently complicated by systemic and organ-specific toxicities. These adverse events often arise because the targeted pathways, such as the PAM (PI3K/AKT/mTOR) or MAPK signaling cascades, are essential for maintaining homeostasis in healthy tissues^[7]. Consequently, inhibition of these nodes can lead to significant treatment-related toxicity, which often limits the therapeutic efficacy of these agents, particularly when used in combination with standard oncological treatments^[7].

Dermatological toxicities are among the most common adverse effects, especially with BRAF inhibitors. These agents, which target the mutant BRAF protein (most notably the V600E mutation), disrupt the MAPK pathway, which is critical for skin homeostasis. Clinical manifestations are diverse, ranging from photosensitivity to the development of keratoacanthomas and squamous cell carcinoma. The mechanism is often linked to the paradoxical activation of germline RAS mutations in healthy cells, which disrupts normal skin function and results in a higher incidence of these side effects. ^[10]

Systemic toxicities also require vigilant management:

• Fever: A frequent systemic reaction that may necessitate temporary dose interruption or the use of antipyretic agents.
• Hepatotoxicity: Liver function tests must be monitored regularly, as BRAF inhibitors are associated with liver toxicity. ^[10]
• Immune Dysregulation: Targeted therapies, including BRAF and MEK inhibitors, can trigger immune dysregulation reactions (DISRs). These are distinct from typical chemotherapy-induced toxicities and require an understanding of the drug's immunomodulatory effects. ^[10]
• Sarcoid-like reactions: Targeted therapies are increasingly associated with sarcoid-like reactions. Because these reactions often present with overlapping clinical and histopathological features, they are frequently misdiagnosed, leading to unnecessary or inappropriate clinical management. ^[10]

In pediatric or older adult populations, the threshold for dose reduction is often lower due to the potential for cumulative toxicity. In low-resource settings, where frequent monitoring of liver enzymes or dermatological surveillance may be limited, the risk of severe, unmanaged toxicity is significantly higher.

Monoclonal antibodies represent a cornerstone of biologic therapy, engineered to bind with high specificity to target antigens expressed on tumor cells, immune cells, or elements of the vascular and extracellular matrix microenvironment. The mechanisms by which these therapies operate include direct receptor blockade, antibody-dependent cellular cytotoxicity, complement activation, and immune checkpoint modulation. The pathway for checkpoint inhibition supporting clinical outcomes with programmed cell death protein 1 (PD-1) and programmed cell death ligand 1 (PD-L1) inhibitors is relatively well characterized. Conversely, the exact downstream mechanisms by which certain novel agents affect long-term survival remain elusive, such as those acting through platelet-derived growth factor receptor-alpha (PDGFR-alpha) inhibition. ^[1]

Among the 25 comparisons showing at least a 4-month difference in delta post-progression survival, 16 showed significant overall survival benefits favoring the biologic or targeted therapy, whereas 9 showed no overall survival benefit for patients treated with the experimental regimen. Investigations of biologic and targeted therapies that successfully improved overall survival evaluated distinct regimens across multiple malignancies. These included pembrolizumab and nivolumab targeting immune checkpoints, alongside gefitinib and erlotinib targeting epidermal growth factor receptors in non-small cell lung cancer (NSCLC). Other proven regimens include trastuzumab and lapatinib in breast cancer and squamous cell carcinoma of the head and neck (SCCHN), rituximab and bortezomib in mantle cell lymphoma, bevacizumab in glioblastoma, vandetanib in small cell lung cancer (SCLC), and olaratumab in soft tissue sarcoma, alongside the novel AKT inhibitor MK-2206. ^[1]

With the exception of MK-2206, which remains in active development, and vandetanib, which was associated with increased toxicity, each of these established agents achieved formal United States Food and Drug Administration (FDA) approval and or National Comprehensive Cancer Network (NCCN) guideline placement for clinical use in their respective disease states. ^[1]

Beyond oncology, examining monoclonal antibody characteristics provides insight into pathogenic immune phenomena, such as heparin-induced thrombocytopenia (HIT). In laboratory analyses of sera from patients with HIT, all nine evaluated patients tested positive in enzyme immunoassays (EIA) and platelet aggregation assays (PEA), confirming the presence of platelet-activating anti-platelet factor 4 (PF4) and heparin antibodies. Of these nine patients, 6 patients, corresponding to 66.7 percent, had a monoclonal antibody detectable by immunofixation electrophoresis (IFE). Affinity-purified anti-PF4 and heparin antibodies from all nine HIT samples successfully activated platelets in the PEA and demonstrated definitive monoclonality when analyzed via mass spectrometry (MS). Following affinity purification, antibody-depleted sera lost both binding activity in the EIA and functional activity in the PEA, thereby confirming the complete removal of the pathogenic antibodies. ^[3]

Epitope mapping of these anti-PF4 and heparin antibodies revealed greater than 70 percent overlap in PF4-binding residues between the purified antibodies and the original serum, confirming they represent identical antibodies. The monoclonal affinity-purified antibodies identified by mass spectrometry corresponded directly to the monoclonal proteins detected in patient serum via immunofixation electrophoresis, which became entirely undetectable following depletion. Each individual HIT monoclonal antibody exhibited a distinct molecular weight, suggesting structural differences among patients, although conserved motifs can exist, as observed in vaccine-induced immune thrombotic thrombocytopenia (VITT) antibodies possessing shared complementarity-determining regions (CDRs). ^[3]

Small molecule kinase inhibitors are a class of targeted therapy that block specific enzymes (kinases) involved in cell signalling pathways driving cancer growth. Unlike monoclonal antibodies, these agents are small enough to enter cells and bind intracellular kinase domains, often competing with ATP at the catalytic pocket. Their selectivity varies: some are highly specific for a single mutant kinase, while others inhibit multiple kinases, which broadens both their efficacy and their toxicity profile.

A paradigm example is the BRAF inhibitor class. Activating mutations in the BRAF gene, most commonly V600E, produce a constitutively active mutant BRAF protein that drives continuous activation of the MAPK (mitogen-activated protein kinase) pathway, leading to uncontrolled cellular growth and proliferation. BRAF inhibitors exert antitumor effects by specifically inhibiting this mutant protein, and are used in metastatic melanoma, non-small cell lung cancer, and anaplastic thyroid carcinoma. By blocking this aberrant signalling, they interrupt the central driver of tumour progression. ^[2]

Another important group targets Bruton’s tyrosine kinase (BTK) in B-cell malignancies. First-generation BTK inhibitors, such as ibrutinib, have reshaped treatment but carry significant cardiovascular toxicity. Ibrutinib is consistently associated with atrial fibrillation rates of approximately 12%–16% in clinical trials and real-world cohorts^[1]. ^[4]

Resistance to BTK inhibitors arises through multisite resistance mutations, driving the need for more adaptable approaches^[1]. Emerging strategies include noncovalent inhibitors and dual-mechanism compounds such as LP-168, which bind BTK in mutation-dependent contexts^[1]. BTK degraders like NX-2127 eliminate BTK via the ubiquitin–proteasome system, potentially bypassing kinase-impaired mutations^[1]. Dual LYN/BTK inhibitors such as birelentinib (DZD8586) suppress both BTK-dependent and alternative B-cell receptor signalling^[1]. These next-generation agents target both kinase-dependent and kinase-independent mechanisms, offering a path toward more durable disease control^[1]. ^[4]

Beyond oncology, small molecule kinase inhibitors show anti-inflammatory potential. Nilotinib, ponatinib and sorafenib reduce doxorubicin-mediated phosphorylation of JNK and p38 MAPK, and suppress expression of IL-1β, IL-6 and CXCL1 RNAs and proteins. This suggests they may minimise the proinflammatory effects of doxorubicin. However, whether these effects result exclusively from inhibition of ZAK kinase or from blocking other kinases remains unclear. ^[6]

When evaluating kinase inhibitors in trials, clinicians should interpret PFS and OS together. Post-progression survival (PPS) is the time alive after disease progression, where OS = PFS + PPS. Differential outcomes (e.g. delta PFS > 0 months with delta OS ≤ 0 months) can occur, and among studies with similar post-study therapies, 13.0% showed differential OS/PFS direction of benefit, while 46.3% of studies with imbalanced post-study therapies showed directional differences. No systematic evidence links these differentials to poor design or post-study treatment. ^[1]

The evaluation of biologic agents and targeted therapies requires a thorough understanding of how these treatments interact with immune signaling pathways, including those involving interleukins and their receptors. From first principles, targeted agents often modulate precise molecular pathways, which can lead to complex patterns of disease response and survival outcomes that differ from traditional cytotoxic treatments. For instance, Toll-like receptors and interleukin-1 receptors share intracellular Toll/interleukin-1 receptor domains that recruit the adaptor protein MyD88, subsequently activating downstream kinases such as IRAK1 and transcription factors like NF-kappaB.

When assessing clinical trials of novel biologic and targeted therapies, clinicians must look closely at the relationship between progression-free survival and overall survival. While progression-free survival and overall survival are normally related because overall survival comprises progression-free survival plus post-progression survival, the introduction of biologic agents frequently disrupts this straightforward correlation. Some novel targeted and immunologic agents demonstrate relatively low progression-free survival improvements alongside dramatic improvements in overall survival, driven by long periods of post-progression survival.

Research into trial outcomes indicates that approximately 10 percent of comparisons show a substantial difference of at least 4 months in overall survival versus progression-free survival benefits when compared to non-biologic or targeted comparators. Among those particular comparisons, slightly over half, or specifically 64 percent, showed an enhanced benefit in overall survival versus the comparator. This suggests that observing a short progression-free survival paired with a long overall survival is often a reflection of the specific mechanism of action rather than an artifact of suboptimal trial design. Furthermore, the absolute magnitude of post-progression survival for patients treated with biologic or targeted therapy averages 9.7 months with a standard deviation of 7.4 months, which is remarkably similar to the absolute magnitude observed in non-biologic comparators averaging 9.8 months with a standard deviation of 7.6 months. ^[1]

Evaluating the quality of evidence is vital. Published studies generally demonstrate high methodological rigour, with average PeDRO quality scores reaching 7.7 out of 10. Only a small minority of 12.6 percent are considered low-quality studies, and a majority of those low-quality trials were never formally published outside of clinical trial registry records. Moreover, regarding post-study care, while nearly two-thirds of studies do not document subsequent therapies, among the 33.5 percent of studies that did report these data, over 64 percent demonstrated clear differences in the subsequent treatments received by trial arms. ^[1]

Despite their high specificity, targeted therapies are increasingly implicated in drug-induced sarcoid-like reactions. Because these agents modulate intricate networks like the Bruton tyrosine kinase and Toll-like receptor pathways, the resulting immune modulation can trigger overlapping clinical and histopathological features that hinder accurate epidemiological data collection and complicate diagnosis. Clinicians must remain vigilant for these inflammatory complications while interpreting survival endpoints in patients receiving modern biologic interventions.

Biologic agents and targeted therapies differ fundamentally from conventional cytotoxic chemotherapy. Rather than non-specifically damaging all rapidly dividing cells, these agents are designed to interfere with specific molecular pathways that drive malignant transformation, tumour proliferation, or immune evasion. Their mechanisms of action can be grouped into several broad categories: monoclonal antibodies targeting cell-surface receptors, small-molecule inhibitors of intracellular kinases, immune checkpoint inhibitors, and agents that remodel the tumour microenvironment (TME).

A key mechanistic principle is that the biological effect of these agents depends not only on the drug itself but on the complex interaction between the therapy and the tumour microenvironment^[1]. This explains why the same agent can produce strikingly different outcomes across tumour types and patient populations. For example, the most common tumour sites studied in trials of biologic/targeted agents include lung (31.3%), breast (12.5%), colorectal (9.4%), gastric/oesophageal (8.9%), pancreatic (6.8%), gynaecologic (4.2%) and glioblastoma (4.2%)^[1] – each with distinct microenvironments that modulate drug response.

Among the most instructive targeted agents are Bruton's tyrosine kinase (BTK) inhibitors. BTK is a critical signalling molecule in B-cell development and activation. BTK inhibitors work by blocking this kinase, thereby disrupting B-cell receptor signalling and survival pathways in malignant B-cells. Importantly, BTK inhibitors also downregulate PD-1/PD-L1, CTLA-4 and other immunosuppressive molecules, which improves responsiveness to immune checkpoint blockade and enhances the efficacy of cellular immunotherapy. This dual mechanism – direct anti-tumour effect plus immune modulation – provides a strong biological rationale for combination strategies involving CAR-T therapy, immune checkpoint inhibitors, CD20-targeted antibodies, BCL2 inhibitors and haematopoietic stem cell transplantation. ^[4]

Toxicities of biologic and targeted agents are equally mechanism-dependent. A distinctive class of adverse effects is the drug-induced sarcoid-like reaction (DISR), which closely mimics sarcoidosis with non-necrotizing epithelioid granulomas. These reactions are thought to arise from an aberrant immune response in genetically predisposed individuals, triggered by two main mechanisms related to the targeted therapy. The specificity of molecular targeting does not eliminate off-target or on-target-but-unwanted effects.

Pharmacokinetic limitations affect large-molecule degraders, and safety signals such as arrhythmia have emerged with newer agents. Furthermore, resistance mutations (e.g., A428D in BTK) illustrate ongoing evolutionary adaptation under therapeutic pressure. The clinical value of next-generation agents therefore depends not only on potency or novel mechanisms but also on rational sequencing, safety optimisation and dynamic treatment monitoring. ^[4]

Biologic and targeted agents function by modulating specific molecular pathways that are often dysregulated in malignancy. At the primary level, these agents frequently target receptor tyrosine kinases (RTKs) or G-protein coupled receptors (GPCRs). Growth factor-mediated induction of RTKs or GPCRs usually initiates the canonical pathway that engenders the activation of AKT, resulting in plasma membrane localization and induction of one, or more isoforms of the class I PI3K family. By inhibiting these receptors, targeted therapies aim to arrest the signalling cascades that drive uncontrolled cellular proliferation and survival. ^[7]

The pharmacodynamic efficacy of these agents is often evaluated through clinical trial outcomes, specifically progression-free survival (PFS) and overall survival (OS). Unlike traditional cytotoxic agents, targeted therapies can exhibit complex survival patterns where the magnitude of benefit in PFS does not always mirror the benefit in OS. Research indicates that approximately 10% of comparisons showed a substantial (greater than or equal to 4 month) difference in OS/PFS benefits versus non-biologic/targeted comparators. Among those, slightly over half (n=16, 64%) showed a benefit in OS versus the comparator, suggesting that the phenomenon of long OS and short PFS or vice versa may not be simply an artifact or a reflection of suboptimal trial design, but could possibly be due to their specific mechanism of action. The observed OS and PFS benefits of these agents are likely due to the unique mechanism of action of these drugs, which should be better understood as the use of these novel agents increases and further scientific evidence is generated. ^[8]

Clinical resistance remains a significant pharmacodynamic challenge. Alterations in epidermal growth factor receptor (EGFR), fibroblast growth factor receptor (FGFR), platelet-derived growth factor receptor (PDGFR), vascular endothelial growth factor receptor (VEGFR), hepatocyte growth factor (HGF), leukocyte receptor tyrosine kinase (LTK), and insulin receptor (INSR) family genes make a significant contribution to treatment failure mainly through the activation of PAM pathway. ^[7]

The pharmacokinetic profile of biologic and targeted agents is highly heterogeneous, necessitating careful dosing strategies. Researchers quantify the clinical impact by calculating the difference in median months of OS and PFS (delta OS and delta PFS) between biologic/targeted and comparator therapy. Across 206 pairwise comparisons, biologic/targeted therapies improved both OS and PFS an average of 1.2 months (SD: 3.8 and 2.5, respectively) versus non-biologic/targeted therapy. ^[8]

The range of outcomes is broad, reflecting the variability in drug metabolism and patient-specific factors. Overall survival associated with the biologic/targeted therapy ranged from 9.8 months lower than the comparator to a gain of 25.4 months versus the comparator. Similarly, PFS associated with the biologic/targeted therapy ranged from 8.2 months lower than the comparator to 14.9 months more than the comparator. ^[8]

Illustrative example: If a patient is treated with a novel kinase inhibitor, the clinician must monitor for toxicity, as seen with agents like vandetanib, which was associated with increased toxicity. In contrast, agents such as pembrolizumab, nivolumab, gefitinib, and erlotinib in NSCLC, or trastuzumab in breast cancer, have established FDA approval and NCCN guideline placement. ^[8]

Pharmacokinetic considerations for special populations:

• Older adults: Often require dose adjustments due to reduced renal or hepatic clearance, which can alter the half-life of small-molecule inhibitors.
• Pregnancy: Many biologic agents are monoclonal antibodies (IgG), which can cross the placenta, particularly in the third trimester, potentially affecting the foetus.
• Low-resource settings: The complexity of monitoring these agents, which often require cold-chain storage and frequent laboratory assessment, can limit their implementation.
• Children: Dosing is frequently weight-based or body-surface-area-based to account for differences in volume of distribution compared to adults.

B-cell malignancies. Over the past decade, BTK inhibitors have reshaped the therapeutic landscape of B-cell malignancies, driving a paradigm shift from intensive chemoimmunotherapy toward targeted, oral, and chemotherapy-free treatment strategies. This clinical transformation reflects the central role of BTK in oncogenic B-cell receptor signaling as well as its broader involvement in malignant B-cell survival, proliferation, adhesion, migration, and tissue homing. By interrupting these interconnected processes, BTK inhibitors have established themselves as foundational agents across multiple B-cell malignancy settings. Diseases in this category include chronic lymphocytic leukaemia, mantle cell lymphoma, Waldenström macroglobulinaemia, and marginal zone lymphoma—all of which depend heavily on constitutive BCR signalling for survival. ^[4]

Immune-mediated diseases. Beyond haematological oncology, BTK inhibitors have expanded into immune-mediated diseases, exemplified by clinical advances and regulatory approvals in conditions such as immune thrombocytopenia (ITP). This expansion reflects the expression and functional relevance of BTK in B cells and innate immune compartments, where it participates in autoantibody production, Fc receptor-mediated effector responses, macrophage activation, mast-cell signalling, and inflammatory modulation. BTK inhibition has thus evolved from a single-agent strategy focused on malignant B-cell signalling into a broader therapeutic platform integrating targeted inhibition, immune remodelling, and rational combination therapy. ^[4]

Drug-induced sarcoid-like reactions (DISRs). A less common but clinically important correlation of targeted therapies is the development of drug-induced sarcoid-like reactions. DISRs represent a rare and poorly understood complication of targeted therapies, and they are almost indistinguishable from sarcoidosis in their clinical, radiological, and histopathological presentation, with resolution upon withdrawal of the causative drug remaining the key distinguishing feature. No specific immuno ^[2]

Combination therapy contexts. Emerging clinical and translational evidence also supports the use of BTK inhibitors in conjunction with CAR-T cell therapies. For instance, pirtobrutinib, a noncovalent, reversible BTK inhibitor, is currently under investigation as a bridging and maintenance agent in combination with the bispecific anti-CD19/CD20 CAR-T product LV20.19. Early data from a dedicated Phase 1 study (NCT05990465) suggest that pirtobrutinib (administered at 200 mg daily) is both feasible and safe in this setting, showing no adverse effects on T-cell immunophenotype and a trend toward enhanced CAR-T functionality. Favorable clinical responses and manageable toxicity were reported in early experiences, justifying further investigation. ^[4]

Current preclinical and limited clinical evidence also supports the feasibility of combining BTK inhibitors with immune checkpoint inhibitors (ICIs), particularly in patients with immunosuppressive tumour microenvironments or T-cell exhaustion following CAR-T cell therapy. ^[4]

Laboratory use also extends to the detection of drug-induced skin reactions (DISR), which have been reported with monoclonal antibodies including Natalizumab, Tocilizumab, Rituximab, Ustekinumab, Trastuzumab, and Dupilumab, with Rituximab accounting for the highest number of reported cases. When such reactions occur, the vast majority of cases are managed by discontinuing the drug (75%, 45 cases), while in 12 cases etanercept was continued. Corticosteroid therapy was the most commonly employed treatment, used in 34 cases, administered either systemically or topically in cases of uveitis. Other immunosuppressive therapies reported include methotrexate (six cases), as well as azathioprine, cyclosporine, and leflunomide (one case each). In most cases, treatment led to resolution: 28 out of 38. ^[2]

When considering targeted therapies and biologic agents in specialized clinical scenarios, understanding unique toxicities, resistance patterns, and patient populations is essential for safe prescribing. Bruton tyrosine kinase (BTK) inhibitors, while transformative in B-cell malignancies, carry distinct class-specific adverse events that require careful monitoring. On-target inhibition of BTK in platelets disrupts glycoprotein VI-mediated signaling and impairs primary hemostasis. This results in an increased incidence of bleeding events, which are predominantly low-grade manifestations such as ecchymosis or petechiae, while major hemorrhage remains relatively uncommon at approximately 3% to 6% across different agents. ^[4]

Hematologic toxicities also demand vigilance. Neutropenia is frequently observed and may vary across agents; for example, zanubrutinib has been associated with a higher incidence of grade 3 or higher neutropenia at approximately 18% to 22%, which potentially reflects its more complete and sustained BTK occupancy. Beyond cytopenias, BTK inhibition exerts broader immunomodulatory effects by impairing macrophage and neutrophil function. Furthermore, resistance remains a clinical hurdle. Non-C481 mutations in the BTK kinase domain can confer resistance to both covalent and noncovalent BTK inhibitors, including pirtobrutinib. These findings highlight the limitations of ATP-competitive inhibition in the setting of structurally diverse resistance variants and have prompted the development of next-generation agents designed to achieve broader target engagement and more durable pathway suppression. ^[4]

In the context of cellular therapies and combination regimens, bridging approaches continue to be evaluated in heavily pretreated populations. BTK inhibitor-based bridging, alone or combined with venetoclax, has demonstrated clinical feasibility in these complex cohorts. Although cytokine release syndrome (CRS) was common across studies at approximately 80% to 90%, the incidence of severe CRS of grade 3 or higher remained relatively low at 8% to 10%, and toxicities including neurologic events and cytopenias were generally manageable. ^[4]

Drug-induced skin reactions (DISRs) are another important consideration associated with biologic therapies, such as anti-tumour necrosis factor alpha (anti-TNFa) agents. DIRS associated with other anti-TNFa agents, such as adalimumab and infliximab, exhibited similar clinical and radiological characteristics to those observed with etanercept. Pulmonary and or mediastinal involvement, along with cutaneous manifestations, were the most reported features. Infliximab was associated with only two cases of uveitis and adalimumab with seven cases of uveitis. The onset of symptoms occurred after an average of 3.6 years for infliximab and 1.3 years for adalimumab. Managing these skin reactions involves several therapeutic options, including careful follow-up, drug discontinuation, topical corticosteroids for localized symptoms, systemic corticosteroids for more widespread involvement, and, when needed, immunomodulatory therapies. ^[2]

Biologic agents and targeted therapies represent a cornerstone of modern disease management, acting via highly specific mechanisms against molecular pathways, cytokines, or cell surface receptors. Despite being highly selective agents, these drugs have been associated with various adverse events, including granulomatous infections such as tuberculosis, leprosy, and leishmaniasis, malignancies such as lymphoma, hematologic disorders including anemia and pancytopenia, demyelinating conditions, worsening congestive heart failure, and hypersensitivity reactions. ^[2]

Targeted therapies also include kinase inhibitors and monoclonal antibodies directed against specific cellular targets. For instance, Bruton tyrosine kinase (BTK) blockade represents a therapeutic strategy for multiple sclerosis and could enhance the efficacy of anti-CD20 therapies such as rituximab. Certain BTK inhibitors penetrate the blood-brain barrier and suppress central nervous system-intrinsic autoreactive B cells and microglial activation. Tolebrutinib is an irreversible BTK inhibitor with high blood-brain barrier penetration that binds to the C481 site, leading to a dose-dependent reduction in new gadolinium-enhancing lesions after 12 weeks of treatment in a phase II trial of patients with multiple sclerosis, with good tolerability and no treatment-related discontinuations. Fenebrutinib, a noncovalent, reversible BTK inhibitor, demonstrated good tolerability in a phase II trial of patients with relapsing multiple sclerosis and achieved early, potent, and sustained inhibition of new brain lesions. ^[4]

When evaluating adverse effects, specific drug combinations warrant careful monitoring. Of the 36 cases of drug-induced sarcoidosis-like reactions analyzed in a recent review, 22 occurred in patients receiving dabrafenib in combination with trametinib. Among these, 21 patients were being treated for metastatic melanoma, while one case involved a chiasmatic glioma. The median time to drug-induced sarcoidosis-like reaction onset was 8.9 months, with a range spanning from 1 to 24 months after the i ^[2]

Adverse reactions can also manifest as specific organ-targeted inflammation or immune-mediated phenomena. A case of drug-induced respiratory syndrome secondary to golimumab therapy for ankylosing spondylitis was reported, presenting with bilateral granulomatous anterior uveitis, alongside a case secondary to certolizumab therapy administered for rheumatoid arthritis, characterized by cutaneous papules. Both cases resolved following the discontinuation of the biologic therapy and initiation of corticosteroid treatment. ^[2]

When managing older patients, physiological changes must be considered. Age-related increases in toxicity may reflect reduced physiological reserve and diminished tolerance to multiagent therapy, which can lead to dose modifications or treatment discontinuation. Such treatment interruptions may in turn attenuate the potential therapeutic benefit of combination strategies. Accordingly, in older patients, incorporating BTK inhibitors into combination regimens requires careful assessment of treatment-related risks and close clinical monitoring to optimize the balance between efficacy and tolerability. ^[4]

The safety profile of biologic and targeted therapies is rarely determined by the drug in isolation. Instead, the risk is context-dependent, influenced by the patient’s underlying disease state and the interplay between chronic inflammation and immune surveillance. In the management of immune-mediated inflammatory diseases (IMIA), the clinician must balance the risk of malignancy against the necessity of disease control. ^[9]

Contraindications are largely dictated by the specific oncologic context. For instance, BRAF inhibitors are specifically indicated for patients with activating mutations such as V600E, which drive uncontrolled cellular growth in conditions like metastatic melanoma, non-small cell lung cancer, and anaplastic thyroid carcinoma. Using these agents outside of their targeted oncologic context is generally contraindicated due to the risk of off-target toxicity without therapeutic benefit.

When considering drug-drug interactions, clinicians must be aware that combining PAM pathway inhibitors with other antineoplastic agents often increases the risk of adverse events^[7]. While combination therapy is a trend to overcome treatment resistance, it requires careful titration^[7]. Furthermore, clinicians should avoid "therapeutic nihilism"—the assumption that treatment is futile—and instead adopt risk-stratified precision prescribing.

Illustrative example: A patient with metastatic melanoma and a V600E mutation is started on a BRAF inhibitor. If the patient develops a sarcoid-like reaction, the clinician must distinguish this from disease progression. Misdiagnosis here could lead to the inappropriate cessation of a life-extending therapy.

Finally, clinicians should note that the survival benefit of these agents is complex. Studies show that the average absolute magnitude of post-progression survival (PPS) is 9.7 months for biologic/targeted therapy, compared to 9.8 months for comparators. Because 29.3% of studies in some cohorts report no OS benefit, clinicians must ensure that the decision to continue therapy is based on clear evidence of clinical benefit rather than an assumption of efficacy. ^[8]

Immune checkpoint inhibitors (ICIs) target two main regulatory pathways, namely the cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and the programmed death-1 (PD-1) pathway. Among these, Ipilimumab was the first drug in this class, receiving approval in 2011 for metastatic melanoma. The PD-1 receptor expressed by T lymphocytes is targeted by Nivolumab and Pembrolizumab, whereas Atezolizumab, Durvalumab, and Avelumab bind directly to the PD-L1 ligand present on cancer cells. Understanding this receptor-ligand distinction is vital for clinical board examinations. ^[2]

Beyond checkpoint inhibitors, targeted therapies encompass kinase inhibitors and novel cellular machinery disruptors. Birelentinib (DZD8586) is the first noncovalent dual BTK/LYN inhibitor with full blood-brain barrier penetration, blocking both BTK-dependent and BTK-independent B-cell receptor signaling. It overcomes bypass signaling pathways and degrader-associated mutations while sparing other TEC family kinases. It has received FDA Fast Track designation for relapsed or refractory chronic lymphocytic leukemia and small lymphocytic lymphoma (R/R CLL/SLL), and is evaluated in phase 1 and phase 2 trials such as TAI-SHAN5 and TAI-SHAN8. ^[4]

Current research in hematological malignancies has shifted toward fixed-duration, Bruton tyrosine kinase inhibitor (BTKi) centered triplet regimens, combining BTK inhibitors with venetoclax and obinutuzumab. These combinations achieve higher undetectable minimal residual disease (MRD) rates and superior progression-free survival compared with traditional chemoimmunotherapy. For instance, a time-limited triplet regimen of pirtobrutinib, venetoclax, and obinutuzumab achieved undetectable MRD at a sensitivity of 10-6 in 80%-85% of patients at 12 months. ^[4]

A major pitfall in managing patients on biologic agents and targeted therapies is failing to recognize drug-induced secondary reactions or atypical manifestations. For instance, the majority of patients treated with anti-TNF-alpha who developed drug-induced sarcoidosis-like reactions (DISR) exhibited pulmonary involvement, whereas patients treated with other drug categories such as BRAF inhibitors showed cutaneous involvement as the most common symptom.

When evaluating radiological findings in patients suspected of developing DISR, clinicians must remember that chest computed tomography scans frequently reveal mediastinal lymphadenopathy alongside parenchymal involvement. Clinicians should also be aware that miscellaneous agents, including interleukin inhibitors (Abatacept) and ALK inhibitors (Lorlatinib), have been linked to DISR in published case literature, mandating high clinical vigilance. ^[2]

Another clinical pitfall involves underestimating the complexity of microbial resistance when deploying biologic treatments in chronic infections. Biofilm communities of bacteria encased in a polymeric matrix protect resident microbes from both conventional antibiotics and host immune effectors. Biofilm matrices are highly variable, typically comprising proteins, carbohydrates, and extracellular DNA. Furthermore, clinical biofilms within chronic and recurrent disease sites are commonly polymicrobial, featuring multiple species or genera acting together, which complicates targeted monoclonal or antimicrobial eradication strategies. ^{[5] [2]}

In contemporary clinical practice, targeted therapies and biologic agents form the cornerstone of management across oncology, hematology, and immunology. Immune checkpoint inhibitors are standard first-line or salvage treatments for numerous metastatic solid tumours, utilizing agents such as Ipilimumab, Nivolumab, Pembrolizumab, Atezolizumab, Durvalumab, and Avelumab. In hematology, BTK inhibitors and novel cellular degraders are deployed for B-cell malignancies, shifting paradigms toward chemotherapy-free, fixed-duration triplet regimens.

In clinical trials, frontline settings are actively investigating advanced regimens. An ongoing phase 2 trial, NCT06333262, is evaluating fixed-duration pirtobrutinib plus obinutuzumab in previously untreated CLL. Similarly, Birelentinib is evaluated in clinical evaluation through phase 1 trial NCT05824585 and phase 2 trial NCT06539182 for high-risk CLL/SLL and B-NHL. These trials underscore the transition from continuous monotherapy to finite, high-efficacy combination approaches designed to deepen molecular remissions. ^[4]

Beyond systemic cancer therapies, understanding molecular pathways informs anti-inflammatory strategies. Mitogen-activated protein kinases (MAPKs) play vital roles in inflammatory diseases. When MAPK activation is blocked in vitro using specific inhibitors such as SB 203580 and ML3403, the inflammatory and pro-apoptotic effects of doxorubicin are suppressed. Because inhibition of p38 MAPK may result in compensatory increased activity of JNK, it can be essential to block both JNK and p38 MAPK to achieve maximal suppression of the downstream effects of MAPK signaling, including toxic side effects. ^[6]